


**Claim Amendments**


**Claims 1-70 (canceled).**

**71. (currently amended) A compound or a pharmaceutically acceptable salt thereof,  
wherein:**

**the compound corresponds in structure to of the Formula I:**




**~~or a pharmaceutically acceptable salt thereof, wherein~~  
the structure:**



is a thiazole or isoxazole, wherein:

the thiazole or isoxazole is optionally substituted with one or more substituents independently selected from the group consisting of alkyl, haloalkyl, aryl, heteroaryl, halogen, alkoxyalkyl, aminoalkyl, hydroxy, nitro, alkoxy, hydroxyalkyl, **alkylthio** **thioalkyl**, amino, alkylamino, arylamino, alkylsulfonamide, acyl, acylamino, alkylsulfone, sulfonamide, allyl, alkenyl, methylenedioxy, ethylenedioxy, alkynyl, carboxamide, cyano, and -(CH<sub>2</sub>)<sub>m</sub>COR;  
each m is independently zero, 1, or 2;  
each R is independently selected from the group consisting of hydroxy, alkoxy, alkyl, amino, and sulfone;

A<sup>1</sup> is selected from the group consisting of:



wherein any such substituent is optionally substituted by one or more substituents independently selected from the group consisting of hydroxy, alkyl, alkoxy, alkoxyalkyl, alkylthio ~~thioalkyl~~, haloalkyl, cyano, amino, alkylamino, halogen, acylamino, sulfonamide, and  $-\text{COR}^4$ ;

$\text{X}^{10}$  is  $\text{CH}_2$ , O, S,  $\text{SO}_2$ , CO,  $\text{CF}_2$ , or  $\text{C}(\text{CH}_3)_2$ ;

$\text{X}^{11}$  is  $\text{CH}_2$ , O, S,  $\text{SO}_2$ , CO,  $\text{CF}_2$ , or  $\text{C}(\text{CH}_3)_2$ ;

$\text{X}^{12}$  is  $\text{CH}_2$ , O, S,  $\text{SO}_2$ , CO, or  $\text{C}(\text{CH}_3)_2$ ;

$\text{R}^{10}$  is H,  $\text{CH}_3$ ,  $\text{OCH}_3$ , or  $\text{OH}$ , ~~or~~  $\text{NR}_2$ ;

$\text{R}^{11}$  is H,  $\text{CH}_3$ ,  $\text{OCH}_3$ , or  $\text{OH}$ , ~~or~~  $\text{NR}_2$ ;

$\text{R}^{12}$  is H,  $\text{CH}_3$ ,  $\text{OCH}_3$ , or OH;

each  $\text{R}^4$  is independently hydroxy, alkoxy, alkyl, or amino;

~~as to  $\text{Z}_1$  and  $\text{Z}_2$ :~~

$\text{Z}_1$  is selected from the group consisting of  $\text{CH}_2$ , O,  $\text{CH}_2\text{O}$ , NH, CO, S, SO,  $\text{CH}(\text{OH})$ , and  $\text{SO}_2$ ; [[and]]

Z<sub>2</sub> is a 1-5 carbon linker optionally containing one or more heteroatoms independently selected from the group consisting of O, S, and N;

~~or Z<sub>1</sub>-Z<sub>2</sub> contains a moiety selected from the group consisting of carboxamide, sulfone, sulfonamide, alkenyl, alkynyl, and acyl; or Z<sub>1</sub>-Z<sub>2</sub> contains a 5- or 6-membered aryl or heteroaryl ring, wherein: the heteroaryl ring optionally is substituted with R<sup>e</sup>, and the heteroaryl ring contains 1-3 heteroatoms independently selected from the group consisting of O, N, and S;~~

each R<sup>c</sup> is independently selected from the group consisting of alkyl, haloalkyl, aryl, heteroaryl, halogen, alkoxyalkyl, aminoalkyl, hydroxy, alkoxy, carboxamide, and cyano;

any ~~[[the]]~~ carbon and nitrogen atoms of Z<sub>1</sub> and ~~[[ - ]]~~ Z<sub>2</sub> are optionally substituted by a moiety selected from the group consisting of alkyl, alkoxy, alkylthio thioalkyl, alkylsulfone, aryl, alkoxyalkyl, hydroxy, alkylamino, heteroaryl, alkenyl, alkynyl, carboxyalkyl, halogen, haloalkyl, and acylamino;

~~as to X and Y: X-Y contains a moiety selected from the group consisting of acyl, alkyl, sulfonyl, amino, ether, thioether, carboxamido, sulfonamido, aminosulfonyl and olefins; or~~

X is selected from the group consisting of -CHR<sup>e</sup>-, -NR<sup>f</sup>-, -O-, -S-, -SO<sub>2</sub>-, and -CO-;  
~~[[and]]~~

Y is selected from the group consisting of -(CH<sub>2</sub>)<sub>p</sub>-, -CHR<sup>g</sup>-, -NR<sup>g</sup>-, -CO-, and -SO<sub>2</sub>-;

R<sup>e</sup> is selected from the group consisting of H, lower alkyl, alkoxy, cycloalkyl, alkoxyalkyl, hydroxy, alkynyl, alkenyl, haloalkyl, alkylthio thioalkyl, and aryl, wherein: ~~when R<sup>e</sup> is hydroxy,~~

the hydroxy ~~[[group]]~~ can optionally form a lactone with the COR<sup>b</sup> of the CH<sub>2</sub>COR<sup>b</sup> moiety bonded to Y<sup>5</sup>; ~~carboxylic acid function of the chain;~~

R<sup>f</sup> is selected from the group consisting of H, alkyl, aryl, benzyl, and haloalkyl;

each R<sup>g</sup> is independently selected from the group consisting of H, alkyl, haloalkyl, alkoxyalkyl, alkynyl, aryl, heteroaryl, aralkyl, hydroxy, alkoxy, and carboxyalkyl;

p is zero or 1;

as to Y<sup>3</sup>, ~~[[and]]~~ Y<sup>4</sup>, and Y<sup>5</sup>:

Y<sup>5</sup> is carbon, and Y<sup>3</sup> and Y<sup>4</sup> are independently selected from the group consisting of H, alkyl, haloalkyl, halogen, aryl, arakyl, heteroaralkyl, heteroaryl, alkenes, hydroxyalkyl, and alkyne, wherein:

the alkyl ~~chain is straight or branched and~~ optionally contains one or more moieties independently selected from the group consisting of N, O, S, sulfone, sulfonamide sulfonamide, nitrile, carboxamide, carboalkoxy, and [[or]] carboxyl, and

the aryl and heteroaryl rings:

are monocyclic or bicyclic optionally containing 1-5 heteroatoms,

~~may be saturated or unsaturated,~~ and

may optionally be substituted by one or more R<sup>c</sup> substituents;

[[or]]

Y<sup>5</sup> is nitrogen, Y<sup>4</sup> is absent, and Y<sup>3</sup> is selected from the group consisting of H, alkyl, haloalkyl, halogen, aryl, arakyl, heteroaralkyl, heteroaryl, alkenes, hydroxyalkyl, and alkyne, wherein:

the alkyl chain optionally contains one or more moieties independently selected from the group consisting of N, O, S, sulfone, sulfonamide sulfonamide, nitrile, carboxamide, carboalkoxy, and carboxyl, and

the aryl and heteroaryl rings:


are monocyclic or bicyclic optionally containing 1-5

heteroatoms, and

may optionally be substituted by one or more R<sup>c</sup> substituents;

or

Y<sup>5</sup> is carbon, and Y<sup>3</sup>, [[and]] Y<sup>4</sup>, and Y<sup>5</sup> together form a 3-8 membered monocyclic or a 7-11 membered bicyclic ring, ~~B such that the compound of Formula I corresponds in structure to formula IA:~~



wherein the ring: ~~B: optionally contains one or more double bonds,~~

optionally contains one or more moieties independently selected from the group consisting of O, NR<sup>g</sup>, S, CO, and SO<sub>2</sub>, and

optionally is substituted with one or more substituents selected from the group consisting of alkyl, haloalkyl, halogen, haloalkyl, alkoxy, alkyne, cyano, alkylsulfone, sulfonamide, carboalkoxy, and carboxyalkyl;

~~Y<sup>5</sup> is C or N when Y<sup>3</sup> or Y<sup>4</sup> is H; Y<sup>5</sup> is C when Y<sup>3</sup> and Y<sup>4</sup> are both other than H;~~

R<sup>b</sup> is X<sub>2</sub> - R<sup>h</sup>;

X<sub>2</sub> is selected from the group consisting of O, S, and NR<sup>j</sup>; and

R<sup>h</sup> and R<sup>j</sup> are independently selected from the group consisting of H, alkyl, aryl, aralkyl, acyl, and alkoxyalkyl.

72. (currently amended) A compound or salt according to claim 71, wherein:

X is ~~-CH<sub>2</sub>-~~ -CHR<sup>e</sup>-; R<sup>e</sup> is H;


Y is a bond ~~-(CH<sub>2</sub>)<sub>p</sub>~~; p is zero;

Y<sup>5</sup> is a carbon; and

R<sup>b</sup> is OH.


73. (currently amended) A compound or a pharmaceutically acceptable salt thereof,  
wherein:

the compound corresponds in structure to ~~[[of]]~~ the following formula:



~~or a pharmaceutically acceptable salt thereof, wherein:~~


the structure:



is a thiazole or isoxazole, wherein:

the thiazole or isoxazole is optionally substituted with one or more substituents independently selected from the group consisting of alkyl, haloalkyl, aryl, heteroaryl, halogen, alkoxyalkyl, aminoalkyl, hydroxy, nitro, alkoxy, hydroxyalkyl, **alkylthio thioalkyl**, amino, alkylamino, arylamino, alkylsulfonamide, acyl, acylamino, alkylsulfone, sulfonamide, allyl, alkenyl, methylenedioxy, ethylenedioxy, alkynyl, carboxamide, cyano, and  $-(CH_2)_mCOR$ ;  
each m is independently zero, 1, or 2;  
each R is independently selected from the group consisting of hydroxy, alkoxy, alkyl, amino, and sulfone;

$A^1$  is selected from the group consisting of:



wherein any such substituent is optionally substituted by one or more substituents independently selected from the group consisting of hydroxy, alkyl, alkoxy, alkoxyalkyl, **alkylthio thioalkyl**, haloalkyl, cyano, amino, alkylamino, halogen, acylamino, sulfonamide, and  $-COR^4$ ;

$X^{10}$  is  $CH_2$ , O, S,  $SO_2$ , CO,  $CF_2$ , or  $C(CH_3)_2$ ;

$X^{11}$  is  $CH_2$ , O, S,  $SO_2$ , CO,  $CF_2$ , or  $C(CH_3)_2$ ;

$X^{12}$  is  $CH_2$ , O, S,  $SO_2$ , CO, or  $C(CH_3)_2$ ;

$R^{10}$  is H,  $CH_3$ ,  $OCH_3$ , or  $OH$ ; ~~or~~  $NR_2$ ;

$R^{11}$  is H,  $CH_3$ ,  $OCH_3$ , or  $OH$ ; ~~or~~  $NR_2$ ;

$R^{12}$  is H,  $CH_3$ ,  $OCH_3$ , or OH;

each  $R^4$  is independently hydroxy, alkoxy, alkyl, or amino;

~~as to  $Z_1$  and  $Z_2$ ;~~




$Z_1$  is selected from the group consisting of  $CH_2$ , O,  $CH_2O$ , NH, CO, S, SO,  $CH(OH)$ , and  $SO_2$ ; and


$Z_2$  is a 1-5 carbon linker optionally containing one or more heteroatoms independently selected from the group consisting of O, S, and N; ~~or  $Z_1$ - $Z_2$  contains a moiety selected from the group consisting of carboxamide, sulfone, sulfonamide, alkenyl, alkynyl, and acyl; or  $Z_1$ - $Z_2$  contains a 5- or 6-membered aryl or heteroaryl ring, wherein: the heteroaryl ring optionally is substituted with  $R^c$ , and the heteroaryl ring contains 1-3 heteroatoms independently selected from the group consisting of O, N, and S;~~

each  $R^c$  is independently selected from the group consisting of alkyl, haloalkyl, aryl, heteroaryl, halogen, alkoxyalkyl, aminoalkyl, hydroxy, alkoxy, carboxamide, and cyano;

any ~~[[the]]~~ carbon and nitrogen atoms of  $Z_1$  and ~~[[ - ]]~~  $Z_2$  are optionally substituted by a moiety selected from the group consisting of alkyl, alkoxy, alkylthio thioalkyl, alkylsulfone, aryl, alkoxyalkyl, hydroxy, alkylamino, heteroaryl, alkenyl, alkynyl, carboxyalkyl, halogen, haloalkyl, and acylamino;

$Y^3$  is selected from the group consisting of H, alkyl,  ~~$CH_2B_1R^{20}$~~   $CH_2Z^3R^{20}$ ,  $CH_2OH$ ,  $C\equiv C-R^{21}$ ,





$Z^3$   $[[B_1]]$  is O, SO<sub>2</sub>, S, or CO;

R<sup>20</sup> is alkyl or aryl;

R<sup>21</sup> is alkyl, aryl, or alkoxyalkyl;

R<sup>22</sup> is H, alkyl, OCH<sub>3</sub>, OH, halogen, amino, or CN;

**R<sup>23</sup> is H, alkyl, OCH<sub>3</sub>, OH, halogen, amino, or CN;**

R<sup>24</sup> is H, alkyl, OCH<sub>3</sub>, OH, or halogen;

$X^{20}$  is  $\text{CH}_2$  or  $\text{O}$ ;

$X^{21}$  is NH, NCH<sub>3</sub>, O, or S; and

Y<sup>4</sup> is selected from the group consisting of H, alkyl, haloalkyl, halogen, aryl, arakyl, heteroaralkyl, heteroaryl, alkenes, hydroxyalkyl, and alkyne, wherein:

the alkyl ~~chain is straight or branched and~~ optionally contains one or more moieties independently selected from the group consisting of N, O, S, sulfone, sulfonamide sulfonamide, nitrile, carboxamide, carboalkoxy, and **[[or]]** carboxyl, and the aryl and heteroaryl rings:


are monocyclic or bicyclic optionally containing 1-5 heteroatoms, ~~may be saturated or unsaturated, and~~

may optionally be substituted by one or more R<sup>c</sup> substituents.




74. (currently amended) A compound or a pharmaceutically acceptable salt thereof,  
wherein:

the compound corresponds in structure to [[of]] the following formula:



~~or a pharmaceutically acceptable salt thereof, wherein:~~



the structure:




is a thiazole or isoxazole, wherein:

the thiazole or isoxazole is optionally substituted with one or more substituents independently selected from the group consisting of alkyl, haloalkyl, aryl, heteroaryl, halogen, alkoxyalkyl, aminoalkyl, hydroxy, nitro, alkoxy, hydroxyalkyl, alkylthio ~~thioalkyl~~, amino, alkylamino, arylamino, alkylsulfonamide, acyl, acylamino, alkylsulfone, sulfonamide, allyl, alkenyl, methylenedioxy, ethylenedioxy, alkynyl, carboxamide, cyano, and  $-(CH_2)_mCOR$ ;  
each m is independently zero, 1, or 2;  
each R is independently selected from the group consisting of hydroxy, alkoxy, alkyl, amino, and sulfone;

A¹ is selected from the group consisting of:





wherein any such substituent is optionally substituted by one or more substituents independently selected from the group consisting of hydroxy, alkyl, alkoxy, alkoxyalkyl, alkylthio thioalkyl, haloalkyl, cyano, amino, alkylamino, halogen, acylamino, sulfonamide, and -COR<sup>4</sup>;

X<sup>10</sup> is CH<sub>2</sub>, O, S, SO<sub>2</sub>, CO, CF<sub>2</sub>, or C(CH<sub>3</sub>)<sub>2</sub>;

X<sup>11</sup> is CH<sub>2</sub>, O, S, SO<sub>2</sub>, CO, CF<sub>2</sub>, or C(CH<sub>3</sub>)<sub>2</sub>;

X<sup>12</sup> is CH<sub>2</sub>, O, S, SO<sub>2</sub>, CO, or C(CH<sub>3</sub>)<sub>2</sub>;

R<sup>10</sup> is H, CH<sub>3</sub>, OCH<sub>3</sub>, OH, or OH<sub>1</sub>, ~~or~~ NR<sub>2</sub>;

R<sup>11</sup> is H, CH<sub>3</sub>, OCH<sub>3</sub>, OH, or OH<sub>1</sub>, ~~or~~ NR<sub>2</sub>;

R<sup>12</sup> is H, CH<sub>3</sub>, OCH<sub>3</sub>, or OH;

each R<sup>4</sup> is independently hydroxy, alkoxy, alkyl, or amino;

~~as to Z<sub>1</sub> and Z<sub>2</sub>:~~


Z<sub>1</sub> is selected from the group consisting of CH<sub>2</sub>, O, CH<sub>2</sub>O, NH, CO, S, SO, CH(OH), and SO<sub>2</sub>; ~~[[and]]~~

Z<sub>2</sub> is a 1-5 carbon linker optionally containing one or more heteroatoms independently selected from the group consisting of O, S, and N; ~~or Z<sub>1</sub>-Z<sub>2</sub> contains a moiety selected from the group consisting of carboxamide, sulfone, sulfonamide, alkenyl, alkynyl, and acyl; or Z<sub>1</sub>-Z<sub>2</sub> contains a 5- or 6-membered aryl or heteroaryl ring, wherein: the heteroaryl ring optionally is substituted with R<sup>e</sup>, and the heteroaryl ring contains 1-3 heteroatoms independently selected from the group consisting of O, N, and S;~~

each  $R^c$  is independently selected from the group consisting of alkyl, haloalkyl, aryl, heteroaryl, halogen, alkoxyalkyl, aminoalkyl, hydroxy, alkoxy, carboxamide, and cyano;

any ~~[[the]]~~ carbon and nitrogen atoms of  $Z_1$  and ~~[[ - ]]~~  $Z_2$  are optionally substituted by a moiety selected from the group consisting of alkyl, alkoxy, alkylthio ~~thioalkyl~~, alkylsulfone, aryl, alkoxyalkyl, hydroxy, alkylamino, heteroaryl, alkenyl, alkynyl, carboxyalkyl, halogen, haloalkyl, and acylamino;

$Y^3$  is selected from the group consisting of H, methyl, phenyl, ethyl, propyl, isopropyl, phenylmethoxymethyl,




Y<sup>4</sup> is selected from the group consisting of H, alkyl, haloalkyl, halogen, aryl, aralkyl, heteroaralkyl, heteroaryl, alkenes, hydroxyalkyl, and alkyne, wherein:

the alkyl ~~chain is straight or branched and~~ optionally contains one or more moieties independently selected from the group consisting of N, O, S, sulfone, sulfonamide sulfonamide, nitrile, carboxamide, carboalkoxy, ~~[[or]]~~ and carboxyl, and the aryl and heteroaryl rings:

are monocyclic or bicyclic optionally containing 1-5 heteroatoms, ~~may be saturated or unsaturated,~~ and may optionally be substituted by one or more R<sup>c</sup> substituents.

75. (currently amended) A compound or salt according to claim 74, wherein A<sup>1</sup> is:



76. (previously presented) A compound or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of:

(2-{5-[3-(5,6,7,8-Tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-isoxazol-3-yl}-cyclopropyl)-acetic acid;

3-Phenyl-4-{5-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-isoxazol-3-yl}-butyric acid;

3-(2,3-Dihydro-benzofuran-6-yl)-4-{5-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-isoxazol-3-yl}-butyric acid;

3-(3-Fluoro-phenyl)-4-{5-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-isoxazol-3-yl}-butyric acid;

3-Pyridin-3-yl-4-{5-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-isoxazol-3-yl}-butyric acid;

3-Benzo[1,3]dioxol-5-yl-4-{5-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-isoxazol-3-yl}-butyric acid;

3-(2,3-Dihydro-benzofuran-6-yl)-4-{3-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-isoxazol-5-yl}-butyric acid;

3-(3-Fluoro-phenyl)-4-{3-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-isoxazol-5-yl}-butyric acid;

3-Pyridin-3-yl-4-{3-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-isoxazol-5-yl}-butyric acid;

3-Benzo[1,3]dioxol-5-yl-4-{3-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-isoxazol-5-yl}-butyric acid;

(2-{3-[3-(5,6,7,8-Tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-isoxazol-5-yl}-cyclopropyl)-acetic acid;

(2-{4-[3-(5,6,7,8-Tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-thiazol-2-yl}-cyclopropyl)-acetic acid;

3-Phenyl-4-{4-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-thiazol-2-yl}-butyric acid;

3-(2,3-Dihydro-benzofuran-6-yl)-4-{4-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-thiazol-2-yl}-butyric acid;

3-(3-Fluoro-phenyl)-4-{4-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-thiazol-2-yl}-butyric acid;

3-Pyridin-3-yl-4-{4-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-thiazol-2-yl}-butyric acid;

3-Benzo[1,3]dioxol-5-yl-4-{4-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-thiazol-2-yl}-butyric acid;

3-Phenyl-4-{3-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-isoxazol-5-yl}-butyric acid;

3-(2,3-Dihydro-benzofuran-6-yl)-4-{3-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-isoxazol-5-yl}-butyric acid;

3-(3-Fluoro-phenyl)-4-{3-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-isoxazol-5-yl}-butyric acid;

3-Pyridin-3-yl-4-{3-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-isoxazol-5-yl}-butyric acid;

3-Benzo[1,3]dioxol-5-yl-4-{3-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-isoxazol-5-yl}-butyric acid

(2-{5-[3-(5,6,7,8-Tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-isoxazol-3-yl}-cyclopropyl)-acetic acid;

3-Phenyl-4-{5-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-isoxazol-3-yl}-butyric acid;

3-(2,3-Dihydro-benzofuran-6-yl)-4-{5-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-isoxazol-3-yl}-butyric acid;

3-(3-Fluoro-phenyl)-4-{5-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-isoxazol-3-yl}-butyric acid;

3-Pyridin-3-yl-4-{5-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-isoxazol-3-yl}-butyric acid;

3-Benzo[1,3]dioxol-5-yl-4-{5-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-isoxazol-3-yl}-butyric acid;

3-(2,3-Dihydro-benzofuran-6-yl)-4-{3-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-isoxazol-5-yl}-butyric acid;

3-(3-Fluoro-phenyl)-4-{3-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-isoxazol-5-yl}-butyric acid;

3-Pyridin-3-yl-4-{3-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-isoxazol-5-yl}-butyric acid;

3-Benzo[1,3]dioxol-5-yl-4-{3-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-isoxazol-5-yl}-butyric acid;

(2-{3-[3-(5,6,7,8-Tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-isoxazol-5-yl}-cyclopropyl)-acetic acid;

(2-{4-[3-(5,6,7,8-Tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-thiazol-2-yl}-cyclopropyl)-acetic acid;

3-Phenyl-4-{4-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-thiazol-2-yl}-butyric acid;

3-(2,3-Dihydro-benzofuran-6-yl)-4-{4-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-thiazol-2-yl}-butyric acid;

3-(3-Fluoro-phenyl)-4-{4-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-thiazol-2-yl}-butyric acid;

3-Pyridin-3-yl-4-{4-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-thiazol-2-yl}-butyric acid;

3-Benzo[1,3]dioxol-5-yl-4-{4-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-thiazol-2-yl}-butyric acid;

Phenyl-4-{3-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-isoxazol-5-yl}-butyric acid;

3-(2,3-Dihydro-benzofuran-6-yl)-4-{3-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-isoxazol-5-yl}-butyric acid;

3-(3-Fluoro-phenyl)-4-{3-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-isoxazol-5-yl}-butyric acid;

3-Pyridin-3-yl-4-{3-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-isoxazol-5-yl}-butyric acid; and

3-Benzo[1,3]dioxol-5-yl-4-{3-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-isoxazol-5-yl}-butyric acid.

77. **(previously presented)** A pharmaceutical composition comprising a therapeutically effective amount of a compound or salt of claim 71 and a pharmaceutically acceptable carrier.

78. **(previously presented)** A pharmaceutical composition comprising a therapeutically effective amount of a compound or salt of Claim 76 and a pharmaceutically acceptable carrier.

79. **(currently amended)** A pharmaceutical composition comprising a therapeutically effective amount of at least one compound or salt of Claim 71 and a pharmaceutically acceptable carrier ~~or additive~~ and **optionally** a cytotoxic agent.

80. **(currently amended)** A pharmaceutical composition comprising a therapeutically effective amount of at least one compound or salt of Claim 76 and a pharmaceutically acceptable carrier ~~or additive~~ and **optionally** a cytotoxic agent.

81. **(previously presented)** A method for treating a condition mediated by  $\alpha_v\beta_3$  integrin selected from the group consisting of tumor metastasis, solid tumor growth, angiogenesis, osteoporosis, humoral hypercalcemia of malignancy, smooth muscle cell migration, restenosis, atherosclerosis, macular degeneration, retinopathy and arthritis in a mammal in need of such treatment comprising administering an effective  $\alpha_v\beta_3$  inhibiting amount of a compound or salt of Claim 71.

82. **(previously presented)** A method for treating a condition mediated by  $\alpha_v\beta_3$  integrin selected from the group consisting of tumor metastasis, solid tumor growth, angiogenesis, osteoporosis, humoral hypercalcemia of malignancy, smooth muscle cell migration, restenosis, atherosclerosis, macular degeneration, retinopathy and arthritis in a mammal in need of such treatment comprising administering an effective  $\alpha_v\beta_3$  inhibiting amount of a compound or salt of claim 76.

**Claims 83 and 84 (canceled).**

85. **(previously presented)** A pharmaceutical composition comprising a therapeutically effective amount of a compound or salt of claim 73 and a pharmaceutically acceptable carrier.

86. **(currently amended)** A pharmaceutical composition comprising a therapeutically effective amount of at least one compound or salt of claim 73 and a pharmaceutically acceptable carrier ~~for additive~~ and **optionally** a cytotoxic agent.

87. **(previously presented)** A method for treating a condition mediated by  $\alpha_v\beta_3$  integrin selected from the group consisting of tumor metastasis, solid tumor growth, angiogenesis, osteoporosis, humoral hypercalcemia of malignancy, smooth muscle cell migration, restenosis, atherosclerosis, macular degeneration, retinopathy and arthritis in a mammal in need of such treatment comprising administering an effective  $\alpha_v\beta_3$  inhibiting amount of a compound or salt of claim 73.



**Claim 88 (canceled).**

89. **(previously presented)** A pharmaceutical composition comprising a therapeutically effective amount of a compound or salt of claim 74 and a pharmaceutically acceptable carrier.


90. **(currently amended)** A pharmaceutical composition comprising a therapeutically effective amount of at least one compound or salt of claim 74 and a pharmaceutically acceptable carrier ~~/or additive~~ and ~~optionally~~ a cytotoxic agent.

91. **(previously presented)** A method for treating a condition mediated by  $\alpha_v\beta_3$  integrin selected from the group consisting of tumor metastasis, solid tumor growth, angiogenesis, osteoporosis, humoral hypercalcemia of malignancy, smooth muscle cell migration, restenosis, atherosclerosis, macular degeneration, retinopathy and arthritis in a mammal in need of such treatment comprising administering an effective  $\alpha_v\beta_3$  inhibiting amount of a compound or salt of claim 74.

**Claim 92 (canceled).**


93. **(currently amended)** A compound or a pharmaceutically acceptable salt thereof, wherein:

the compound corresponds in structure to of the Formula I:



~~or a pharmaceutically acceptable salt thereof, wherein:~~


the structure:



is a thiazole or isoxazole, wherein:

the thiazole or isoxazole is optionally substituted with one or more substituents independently selected from the group consisting of alkyl, haloalkyl, aryl, heteroaryl, halogen, alkoxyalkyl, aminoalkyl, hydroxy, nitro, alkoxy, hydroxyalkyl, **alkylthio thioalkyl**, amino, alkylamino, arylamino, alkylsulfonamide, acyl, acylamino, alkylsulfone, sulfonamide, allyl, alkenyl, methylenedioxy, ethylenedioxy, alkynyl, carboxamide, cyano, and  $-(CH_2)_mCOR$ ; each m is independently zero, 1, or 2; each R is independently selected from the group consisting of hydroxy, alkoxy, alkyl, amino, and sulfone;

$A^1$  is selected from the group consisting of:



wherein any such substituent is optionally substituted by one or more substituents independently selected from the group consisting of hydroxy, alkyl, alkoxy, alkoxyalkyl, **alkylthio thioalkyl**, haloalkyl, cyano, amino, alkylamino, halogen, acylamino, sulfonamide, and  $-COR^4$ ;

X<sup>10</sup> is CH<sub>2</sub>, O, S, SO<sub>2</sub>, CO, CF<sub>2</sub>, or C(CH<sub>3</sub>)<sub>2</sub>;

X<sup>11</sup> is CH<sub>2</sub>, O, S, SO<sub>2</sub>, CO, CF<sub>2</sub>, or C(CH<sub>3</sub>)<sub>2</sub>;

X<sup>12</sup> is CH<sub>2</sub>, O, S, SO<sub>2</sub>, CO, or C(CH<sub>3</sub>)<sub>2</sub>;

R<sup>10</sup> is H, CH<sub>3</sub>, OCH<sub>3</sub>, or OH; ~~or NR<sub>2</sub>~~;

R<sup>11</sup> is H, CH<sub>3</sub>, OCH<sub>3</sub>, or OH; ~~or NR<sub>2</sub>~~;

R<sup>12</sup> is H, CH<sub>3</sub>, OCH<sub>3</sub>, or OH;

each R<sup>4</sup> is independently hydroxy, alkoxy, alkyl, or amino;

**as to Z<sub>1</sub> and Z<sub>2</sub>:**

Z<sub>1</sub> is selected from the group consisting of CH<sub>2</sub>, O, CH<sub>2</sub>O, NH, CO, S, SO, CH(OH), and SO<sub>2</sub>; and

Z<sub>2</sub> is a 1-5 carbon linker optionally containing one or more heteroatoms independently selected from the group consisting of O, S, and N; ~~or Z<sub>1</sub>-Z<sub>2</sub> contains a moiety selected from the group consisting of carboxamide, sulfone, sulfonamide, alkenyl, alkynyl, and acyl; or Z<sub>1</sub>-Z<sub>2</sub> contains a 5- or 6-membered aryl or heteroaryl ring, wherein: the heteroaryl ring optionally is substituted with R<sup>e</sup>, and the heteroaryl ring contains 1-3 heteroatoms independently selected from the group consisting of O, N, and S;~~

each R<sup>c</sup> is independently selected from the group consisting of alkyl, haloalkyl, aryl, heteroaryl, halogen, alkoxyalkyl, aminoalkyl, hydroxy, alkoxy, carboxamide, and cyano;


any ~~[[the]]~~ carbon and nitrogen atoms of Z<sub>1</sub> and ~~[[ ]]~~ Z<sub>2</sub> are optionally substituted by a moiety selected from the group consisting of alkyl, alkoxy, alkylthio ~~thioalkyl~~, alkylsulfone, aryl, alkoxyalkyl, hydroxy, alkylamino, heteroaryl, alkenyl, alkynyl, carboxyalkyl, halogen, haloalkyl, and acylamino;

Y is selected from the group consisting of -(CH<sub>2</sub>)<sub>p</sub>-, -CHR<sup>g</sup>-, -NR<sup>g</sup>-, -CO-, and -SO<sub>2</sub>-;

each R<sup>g</sup> is independently selected from the group consisting of H, alkyl, haloalkyl, alkoxyalkyl, alkynyl, aryl, heteroaryl, aralkyl, hydroxy, alkoxy, and carboxyalkyl;

p is zero or 1;

X and Y<sup>3</sup>, together with the atom(s) to which they are both bonded, form a 3-7 membered monocyclic ring, ~~C such that the compound of Formula I corresponds in structure to formula IB:~~



wherein the ring: ~~C: optionally contains one or more double bonds,~~

optionally contains one or more moieties independently selected from the group consisting of O, NR<sup>g</sup>, S, CO, and SO<sub>2</sub>, and

optionally is substituted with one or more substituents independently selected from the group consisting of alkyl, halogen, alkoxy, haloalkyl, hydroxyalkyl, and alkoxyalkyl;

as to Y<sup>4</sup> and Y<sup>5</sup>:

Y<sup>5</sup> is nitrogen, and Y<sup>4</sup> is absent; or

Y<sup>5</sup> is carbon, and Y<sup>4</sup> is selected from the group consisting of H, alkyl, haloalkyl, halogen, aryl, aralkyl, heteroaralkyl, heteroaryl, alkenes, hydroxyalkyl, and alkyne, wherein:

the alkyl ~~chain is straight or branched and~~ optionally contains one or more moieties independently selected from the group consisting of N, O, S, sulfone, sulfonamide sulfonamide, nitrile, carboxamide, carboalkoxy, and [[or]] carboxyl, and

the aryl and heteroaryl rings:

are monocyclic or bicyclic optionally containing 1-5 heteroatoms,

~~may be saturated or unsaturated,~~ and

may optionally be substituted by one or more R<sup>c</sup> substituents; or

R<sup>b</sup> is X<sub>2</sub> - R<sup>h</sup>;

X<sub>2</sub> is selected from the group consisting of O, S, and NR<sup>j</sup>; and

R<sup>h</sup> and R<sup>j</sup> are independently selected from the group consisting of H, alkyl, aryl, aralkyl, acyl, and alkoxyalkyl.

94. (previously presented) A pharmaceutical composition comprising a therapeutically effective amount of a compound or salt of claim 93 and a pharmaceutically acceptable carrier.

95. **(currently amended)** A pharmaceutical composition comprising a therapeutically effective amount of at least one compound or salt of claim 93 and a pharmaceutically acceptable carrier ~~for additive~~ and **optionally** a cytotoxic agent.

96. **(previously presented)** A method for treating a condition mediated by  $\alpha_v\beta_3$  integrin selected from the group consisting of tumor metastasis, solid tumor growth, angiogenesis, osteoporosis, humoral hypercalcemia of malignancy, smooth muscle cell migration, restenosis, atherosclerosis, macular degeneration, retinopathy and arthritis in a mammal in need of such treatment comprising administering an effective  $\alpha_v\beta_3$  inhibiting amount of a compound or salt of claim 93.

**Claim 97 (canceled).**